SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space
Biotechnology company 180 Life Sciences has launched a variety of advanced clinical and preclinical-stage efforts to develop novel anti-inflammatory treatments for patients with chronic illnessesA planned merger with 180 Life Sciences advanced under a special purpose acquisition corporation (SPAC) is expected to be completed within the next month, resulting in a Nasdaq filing under the ticker ATNF180 Life Sciences’s founders are an experienced team of…